You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
信達生物(01801.HK)稱業務運營一切正常 半日股價跌逾8%
阿思達克 01-05 12:33
信達生物(01801.HK)公佈,公司關注到其股份近期股價及成交量出現不正常波動。公司澄清,業務運營一切正常,對公司發展充滿信心。 公司指,已建立一條擁有26個臨牀不同階段產品的管線,以及超過80個臨牀前立項項目。而公司已擁有6款獲批產品,將繼續做好現有的六款已經上市的產品在國內的推廣工作,其中達伯舒(信迪例單抗注射液)自上市以來,持續保持快速的銷量及銷售額增長,公司有信心今年保持達伯舒的市場領先地位和持續的銷量及銷售額增長。 另外,公司預計未來兩年內至少擴充至十款以上獲批產品,有信心及能力保持業務運營的長期穩健增長。公司亦已建立起六萬升的規模化抗體生產產能,確保滿足產品的充足供應和生產成本優勢。 該股今日中午跌8.25%,收報37.25元,是前年5月以來最低,成交757.3萬股。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account